Spruce Biosciences faces setbacks as tildacerfont trials fail primary endpoints, raising concerns about drug efficacy and compl...

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow...

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarte...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow tr...

RBC Capital analyst Gregory Renza downgrades Spruce Biosciences (NASDAQ:SPRB) from Outperform to Sector Perform and lowers t...

U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow trad...

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Spruce Biosciences (NASDAQ:SPRB) from Buy to Neutral.

Spruce Biosciences' latest CAH studies: CAHmelia-203 & CAHptain-205. Discover insights on tildacerfont's efficacy, ...